Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
Official URL: http://hl7.eu/fhir/ig/gravitate-health/ImplementationGuide/hl7.eu.fhir.gh | Version: 0.1.0 | |||
Active as of 2024-11-22 | Computable Name: GhImplementationGuide |
This FHIR Implementation Guide demonstrates how to integrate patient health information from the International Patient Summary (IPS) with medicinal product information from regulatory approved electronic Product Information (ePI) documents.
Together, the IPS and ePI will facilitate the creation of new digital platforms that give patients a more accessible way of acquiring trusted health and medicinal product Information.
To specify how to:
It is Gravitate Health's vision that engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.
To that end, the Gravitate-Health project aims to:
Gravitate Health is a public – private partnership with 39 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI2 Associated Partners.
A medicine’s product information is a pivotal source of regulated and scientifically validated information that assists healthcare professionals (Summary of Product Characteristics or SmPC) in prescribing and dispensing the medicine and informs consumers about its safe use (Patient Information Leaflet or PIL).
Trusted medicinal product information is based on non-computable formats (i.e., Word or PDF); is difficult to find; difficult to search; and is not meeting patient needs (e.g., available in multiple languages, accessibility support, readability).
As a result, patients and healthcare professionals turn to disparate sources that may or may not be trustworthy or complete. It can also contribute to less than optimal levels of understanding, use, or access to medicinal infromation. This can be a barrier to a citizens active and meaningful participation in their healthcare and clinical research.
Hence the need to transition to a modern electronic platform that resolves issues related to distribution, format and content of medicinal product information.
An International Patient Summary (IPS) document is an electronic health record extract containing essential healthcare information about a subject of care. The IPS is minimal and non-exhaustive; specialty-agnostic and condition-independent; but still clinically relevant. Refer to the IPS Implementation Guide for further detail.
FHIR ePI documents (Refer to section ## for a list of in-scope Resources) FHIR IPS documents (Refer to section ## for a list of in-scope Resources)
It is not in the scope of this Implementation Guide to provide any solutions and strategies for the creation, sharing, mapping, translation, and use of the ePI or IPS.
All resources should be considered out of scope unless explicitly mentioned in this Implementation Guide.
Vulcan FHIR eProduct Info (ePI)
Innovative Medicines Initiative (IMI) Gravitate-Health
European Medicine Agency (EMA) Electronic product information (ePI) for human medicines
EMA ePI API specification v1.0
EMA Substance, product, organisation and referential (SPOR) master data
International Patient Summary (IPS)
Roles | Name | Organization | Contact |
---|---|---|---|
Author | Jens Kristian Villadsen | Trifork | jvi_at_trifork.com |
Author | Craig Anderson | Pfizer | craig.anderson2@pfizer.com |
Author | Giorgio Cangioli | HL7 Europe | giorgio.cangioli_at_gmail.com |